Evidence map›Paper›PMID 29228561›Full record

ArticleOncotarget2017

Enantiomerically pure β-dipeptide derivative induces anticancer activity against human hormone-refractory prostate cancer through both PI3K/Akt-dependent and -independent pathways.

Mei-Ling Chan, Chia-Chun Yu, Jui-Ling Hsu, Wohn-Jenn Leu, She-Hung Chan, Lih-Ching Hsu, Shih-Ping Liu, Polina M Ivantcova, Özdemir Dogan, Stefan Bräse and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Targeting PI3K/Akt signaling in prostate cancer therapy.Journal of cell communication and signaling · 2023
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Mei-Ling ChanSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chia-Chun YuSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Jui-Ling HsuSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Wohn-Jenn LeuSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
She-Hung ChanSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Lih-Ching HsuSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Shih-Ping LiuGraduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Polina M IvantcovaDepartment of Medicinal Chemistry, Faculty of Chemistry, Lomonosov Moscow State University, Moscow, Russian Federation.
Özdemir DoganDepartment of Chemistry, Middle East Technical University, Ankara, Turkey.
Stefan BräseInstitute of Organic Chemistry, Karlsruhe Institute of Technology, Karlsruhe, Germany.
Konstantin V KudryavtsevDepartment of Medicinal Chemistry, Faculty of Chemistry, Lomonosov Moscow State University, Moscow, Russian Federation.
Jih-Hwa GuhSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
National Taiwan University · TWLomonosov Moscow State University · RUKarlsruhe Institute of Technology · DEMiddle East Technical University · TRNational Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of peptides that target cancer cells and induce anticancer activities through various mechanisms is developing as a potential anticancer strategy. KUD983, an enantiomerically pure β-dipeptide derivative, displays potent activity against hormone-refractory prostate cancer (HRPC) PC-3 and DU145 cells with submicromolar IC

Indexed as

c-Mychormone-refractory prostate cancermTORPI3K/Aktβ-dipeptide

Identifiers

PMID29228561
PMCPMC5722513
OpenAlexW2616194990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.